Oramed Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Oramed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company pioneering the development of oral delivery solutions for drugs and therapeutic proteins traditionally administered via injection. Utilizing its proprietary Protein Oral Delivery (POD™) technology platform, the company designs oral dosage forms engineered to withstand the harsh, acidic environment of the gastrointestinal tract and effectively deliver active proteins into the bloodstream. Oramed's primary clinical focus has historically been on oral insulin (ORMD-0801) for the treatment of type 2 diabetes and NASH, alongside oral GLP-1 analogs (ORMD-0901). In early 2026, the company executed a major strategic shift by partnering with Lifeward Ltd. (formerly ReWalk Robotics), transferring its POD™ technology assets and future clinical trial responsibilities to Lifeward's subsidiary, OraTech, in exchange for equity, warrants, and revenue-sharing rights.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Oramed is transitioning from a pure-play clinical-stage biotechnology company into a diversified holding company. It has diversified its capital into structured investments, biotechnology equities (such as Alpha Tau and Scilex), and real estate-backed loans to generate financial income and maximize shareholder value.
Expected impact: Diversifies risk away from single-candidate clinical development, generates volatile but substantial net financial income, and provides liquidity for future operations.
Oramed is advancing a refined oral insulin program independently, focusing on specific high-responder subgroups (such as patients with lower BMI and older demographics) identified through deep-dive analysis of previous Phase 2 and Phase 3 data. The company plans to manage and fund a 60-patient, US-based clinical trial to validate the formulation.
Expected impact: Provides a cost-effective path to validate the robustness of the oral insulin formulation and generate compelling evidence for potential future regulatory submissions or partnerships.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Extremely High. Oramed transferred its proprietary Protein Oral Drug (POD) delivery technology to Lifeward, a revenue-generating medical robotics company [1.2.1]. This allows Oramed to retain clinical exposure to the oral drug delivery platform while gaining a massive equity stake in a commercial-stage medical device business.
Terms: Oramed received a 49.9% beneficial ownership interest in Lifeward (consisting of ordinary shares and pre-funded warrants) and a 4% royalty on net sales of the ReWalk franchise for up to 10 years. Oramed also invested $9 million in Lifeward's senior secured convertible notes (with an option for an additional milestone-based $9 million investment).